Osimertinib
- Generic Name
- Osimertinib
- Brand Names
- Tagrisso
- Drug Type
- Small Molecule
- Chemical Formula
- C28H33N7O2
- CAS Number
- 1421373-65-0
- Unique Ingredient Identifier
- 3C06JJ0Z2O
- Background
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and...
- Indication
Osimertinib is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations (as detected by an FDA-approved test), and as the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGF...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
- Associated Therapies
- First Line Chemotherapy
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
- Conditions
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 248
- Registration Number
- NCT03944772
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
- Conditions
- Interventions
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2024-12-11
- Target Recruit Count
- 140
- Registration Number
- NCT03940703
- Locations
- 🇺🇸
Community Health Network, Indianapolis, Indiana, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇨🇳The First Affiliated Hospital, Zhejiang University, Hangzhou, China
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Xiuning Le
- Target Recruit Count
- 160
- Registration Number
- NCT03909334
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Indiana Univesity Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03891615
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Osimertinib Study in Indian Patients
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT03853551
- Locations
- 🇮🇳
Research Site, New Delhi, India
Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT03831932
- Locations
- 🇺🇸
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
🇺🇸University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT03810807
- Locations
- 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- University Hospital, Essen
- Target Recruit Count
- 16
- Registration Number
- NCT03810066
- Locations
- 🇩🇪
Prof. Dr. med. Martin Schuler, Essen, NRW, Germany
First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Vestre Viken Hospital Trust
- Target Recruit Count
- 100
- Registration Number
- NCT03804580
- Locations
- 🇳🇴
Oslo University Hospital - Ullevaal, Oslo, Norway
🇩🇰Herlev Hospital, Copenhagen, Denmark
🇩🇰Aarhus University Hospital, Aarhus, Denmark
Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive
- Conditions
- First Posted Date
- 2018-12-31
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Fundación GECP
- Target Recruit Count
- 169
- Registration Number
- NCT03790397
- Locations
- 🇪🇸
Hospital Universitario Dr. Negrín, Las Palmas De Gran Canaria, Las Palmas, Spain
🇪🇸Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
🇪🇸ICO Badalona, Badalona, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.